ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
Product details
Registration number: SIN15479P
Classification: Prescription Only
Active ingredients:
- (Acellular Pertussis) Filamentous Haemagglutinin Adsorbed (FHA)
- (Acellular Pertussis) Fimbriae Type 2 and 3 Adsorbed (FIM)
- (Acellular Pertussis) Pertactin Adsorbed (PRN)
- (Acelullar Pertussis) Pertussis Toxoid Adsorbed (PT)
- Diphtheria Toxoid Adsorbed
- Inactivated Poliomyelitis Vaccine (IPV) Type 1 Mahoney
- Inactivated Poliomyelitis Vaccine (IPV) Type 2 (MEF-1)
- Inactivated Poliomyelitis Vaccine (IPV) Type 3 (Saukett)
- Tetanus Toxoid Adsorbed
Strength:
- 5 µg/ 0.5 ml
- 5 µg/0.5 ml
- 3 µg/0.5 ml
- 2.5 µg/ 0.5 ml
- 2Lf
- 40 D-Antigen Units
- 8 D-antigen units
- 32 D-antigen units
- 5Lf
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
ATC code: J07CA02
HSA approval date: 8 May 2018
Manufacturer(s):
- Sanofi Winthrop Industrie (VDR)
- SANOFI PASTEUR LIMITED
Manufacturing country/countries: CANADA; FRANCE
What are the HSA registration number and classification for ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN15479P
Classification: Prescription Only
What active ingredients and strength are recorded for ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE?
According to the HSA dataset updated 7 August 2026:
Active ingredients:
- (Acellular Pertussis) Filamentous Haemagglutinin Adsorbed (FHA)
- (Acellular Pertussis) Fimbriae Type 2 and 3 Adsorbed (FIM)
- (Acellular Pertussis) Pertactin Adsorbed (PRN)
- (Acelullar Pertussis) Pertussis Toxoid Adsorbed (PT)
- Diphtheria Toxoid Adsorbed
- Inactivated Poliomyelitis Vaccine (IPV) Type 1 Mahoney
- Inactivated Poliomyelitis Vaccine (IPV) Type 2 (MEF-1)
- Inactivated Poliomyelitis Vaccine (IPV) Type 3 (Saukett)
- Tetanus Toxoid Adsorbed
Strength:
- 5 µg/ 0.5 ml
- 5 µg/0.5 ml
- 3 µg/0.5 ml
- 2.5 µg/ 0.5 ml
- 2Lf
- 40 D-Antigen Units
- 8 D-antigen units
- 32 D-antigen units
- 5Lf
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, SUSPENSION
Route: INTRAMUSCULAR
Who is the recorded registrant for ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE?
According to the HSA dataset updated 7 August 2026:
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Which manufacturers and countries are listed for ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s):
- Sanofi Winthrop Industrie (VDR)
- SANOFI PASTEUR LIMITED
Manufacturing country/countries: CANADA; FRANCE
Where can I look up ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN15479P or the exact product name ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE. The general register link does not preselect this product.
What are the source dates for this ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this ADACEL®-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN15479P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)